Sign In
Buy PRGO
$9.49
-0.110 (-1.15%)
At Close: Jun 23, 2026
FDA Approves First Over-The-Counter Birth Control Pill in U.S. Perrigo Stock Jumps.
09:45am, Thursday, 13'th Jul 2023
The drug will be available in store and online at retailers across the country 'early in the first quarter of 2024,' the company says.
3 Healthcare Stocks to Buy Amid Market Volatility
09:36am, Thursday, 13'th Jul 2023
Patterson (PDCO), Perrigo (PRGO) and GSK are three healthcare stocks that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
Perrigo's stock soars 6% after FDA approves its over-the-counter daily oral contraceptive
09:02am, Thursday, 13'th Jul 2023
Perrigo Co. PLC's stock PRGO, -0.78% soared 6% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its over-the-counter daily oral contraceptive. The
US FDA approves Perrigo's contraceptive pill for over-the-counter use
08:45am, Thursday, 13'th Jul 2023
The U.S. Food and Drug Administration on Thursday approved the over-the-counter use of Perrigo's contraceptive drug, making it the first non-prescription birth control pill in the United States.
Should Value Investors Buy Perrigo (PRGO) Stock?
11:06am, Wednesday, 12'th Jul 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Are Investors Undervaluing Perrigo (PRGO) Right Now?
10:47am, Thursday, 15'th Jun 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
How Much Upside is Left in Perrigo (PRGO)? Wall Street Analysts Think 49.5%
10:57am, Wednesday, 14'th Jun 2023
The mean of analysts' price targets for Perrigo (PRGO) points to a 49.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Perrigo Outlook Healed By Repositioning
05:30pm, Monday, 12'th Jun 2023
Perrigo is repositioning itself as an exclusively consumer-facing over-the-counter brand, streamlining its sales process, and expanding its market through acquisitions. PRGO's Opill contraceptive is e
Perrigo hires Bayer's ex-U.S. head as new CEO
07:51am, Thursday, 08'th Jun 2023
Perrigo Co. Plc PRGO, +0.51% on Thursday named Patrick Lockwood-Taylor as its new president and chief executive officer as of June 30. Lockwood-Taylor previously worked in dual roles at Bayer AG as pr
Down -16% in 4 Weeks, Here's Why You Should You Buy the Dip in Perrigo (PRGO)
10:45am, Wednesday, 31'st May 2023
The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Is Perrigo (PRGO) Stock Undervalued Right Now?
10:46am, Thursday, 25'th May 2023
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Perrigo Company: Still Not Getting There
03:12pm, Thursday, 18'th May 2023
In 2021, I hoped and anticipated that Perrigo Company plc was leaving its turbulent past behind. The company resolved its issues around its tax situation, but then announced a rather expensive deal as
Gerber baby formula with potential bacteria was shipped to stores after recall: feds
12:38pm, Monday, 15'th May 2023
Certain lots of Perrigo's Gerber Good Start SoothePro powdered infant formula had been recalled in March out of an abundance of caution due to the potential presence of cronobacter sakazakii.
Perrigo CEO Murray Kessler: Over-the-counter birth control is a 'historic opportunity for women'
05:47pm, Friday, 12'th May 2023
Murray Kessler, Perrigo President & CEO, joins 'Closing Bell Overtime' to discuss the FDA's recommendation of Opill, an over the counter birth control pill, as well as new safety measures in baby form
2 Pharma Stocks in Focus on FDA Buzz
10:55am, Thursday, 11'th May 2023
Immunitybio Inc (NASDAQ:IBRX) stock is crumbling today, down 52.1% at $2.98 at last glance, and earlier as low as $2.45, after the U.S. Food and Drug Administration (FDA) declined to approve its blad
